This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Epizyme (EPZM) Reports Narrower Q4 Loss, Pipeline in Focus
by Zacks Equity Research
Epizyme, Inc. (EPZM) reported a loss of 60 cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of 64 cents.
Agenus (AGEN) Reports Narrower-than-Expected Loss in Q4
by Zacks Equity Research
Agenus Inc. (AGEN) reported fourth-quarter 2016 loss of 30 cents per share (including non-cash expenses), narrower than the Zacks Consensus Estimate of a loss of 33 cents but wider than the year-ago loss of 18 cents.
Valeant (VRX) Issues Notes, Restructures Debt; Shares Down
by Zacks Equity Research
Valeant Pharmaceuticals International, Inc. (VRX) commenced an offer to purchase cash up to $600 million of aggregate principal amount due 2018.
Aerie (AERI) Q4 Loss Widens, Rhopressa NDA Resubmitted
by Zacks Equity Research
Aerie Pharmaceuticals, Inc. (AERI) posted fourth-quarter 2016 loss of 87 cents per share (including stock-based compensation), wider than both the Zacks Consensus Estimate of a loss of 65 cents
Novartis (NVS) Reports Positive Data on Biosimilar Humira
by Zacks Equity Research
Novartis AG (NVS) announced encouraging data for its proposed biosimilar verison of AbbVie's (ABBV) Humira.
GlaxoSmithKline's Nucala Positive in Label Expansion Study
by Zacks Equity Research
GlaxoSmithKline plc. (GSK) announced that a phase IIIb study evaluating its respiratory drug Nucala (mepolizumab) met all its primary and secondary endpoints.
Impax (IPXL) Q4 Earnings in Line, Revenues Miss Estimates
by Zacks Equity Research
Impax Laboratories Inc. (IPXL) posted fourth-quarter 2016 adjusted earnings of 16 cents per share, in line with the Zacks Consensus Estimate.
Keryx (KERX) Q4 Loss Wider than Expected, Revenues Beat
by Zacks Equity Research
Keryx Biopharmaceuticals Inc. (KERX) reported fourth-quarter 2016 loss of 32 cents per share, narrower than the year-ago loss of 36 cents. However, the loss was wider than the Zacks Consensus Estimate of a loss of 27 cents per share.
Mylan (MYL) Beats on Q4 Earnings, Stock Up on Strong View
by Zacks Equity Research
Shares of Mylan N.V.'s (MYL) were up 7.2% after the company beat expectations in the fourth-quarter 2016 and provided a strong outlook for 2017 amid challenging conditions.
Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis
by Zacks Equity Research
Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis
Valeant (VRX) Tops Q4 Earnings, Shares Down on Tepid View
by Zacks Equity Research
Valeant's (VRX) fourth-quarter results beat expectations but the guidance of 2017 was disappointing.
Endo (ENDP) Beats on Q4 Earnings, Revenues; Guides Low
by Zacks Equity Research
Endo's (ENDP) Q4 results beat expectations but the outlook for 2017 was disappointing and lagged expectations
by Zacks Equity Research
Pharma Industry Outlook - February/March 2017
by Arpita Dutt
The sector is showing signs of recovery with the NYSE ARCA Pharmaceutical Index gaining 5.1% while the NASDAQ Biotechnology Index is up 7.3%.
Intercept (ICPT) Q4 Loss Wider than Expected, Revenues Beat
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $4.84 per share in the fourth quarter of 2016, wider than the Zacks Consensus Estimate of a loss of $3.58.
Radius Health (RDUS) Posts Wider Loss in Q4
by Zacks Equity Research
Radius Health, Inc. (RDUS) posted a loss of $1.22 per share in the fourth quarter of 2016, compared with a loss of 77 cents per share in the year-ago quarter and wider than the Zacks Consensus Estimate loss of $1.16.
Bayer (BAYRY) Misses on Q4 Earnings; Revenues in Line
by Zacks Equity Research
Bayer AG's (BAYRY) fourth-quarter 2016 core earnings increased 10.2% year over year to ???1.19 per share (approximately $1.28). Reported earnings missed the Zacks Consensus Estimate of $1.37.
Top Ranked Growth Stocks to Buy for February 23rd
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, February 23rd:
Pfizer's Leukemia Candidate Gets Priority Review in U.S.
by Zacks Equity Research
Pfizer Inc. (PFE) announced that its Biologics License Application (BLA) for leukemia candidate inotuzumab ozogamicin has been accepted for priority review by the FDA.
Shire (SHPG) Beats on Q4 Earnings, Sales; Gives Upbeat View
by Zacks Equity Research
Shire's (SHPG) fourth-quarter results were encouraging with the company beating both top- and bottom-line estimates.
Zoetis (ZTS) Beats Q4 Earnings Estimates, Lowers Outlook
by Zacks Equity Research
Zoetis Inc. (ZTS) topped earnings estimates in the fourth-quarter of 2016 while revenues came in line. The company also narrowed its outlook for 2017 to account for currency impact.
Alexion (ALXN) Q4 Earnings In-Line, Sales Rise Y/Y
by Zacks Equity Research
Alexion Pharmaceuticals, Inc.'s (ALXN) fourth-quarter 2016 earnings (including stock-based compensation expense) of $1.10 cents per share compared with the year ago earnings of 78 cents.
Alkermes (ALKS) Q4 Loss Narrower than Expectations, Sales Beat
by Zacks Equity Research
Alkermes plc (ALKS) reported loss of 4 cents per share (including the impact of share-based compensation expense) in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 19 cents.
AMAG Pharma (AMAG) Incurs Loss in Q4, Revenues Lag Estimates
by Zacks Equity Research
AMAG Pharmaceuticals, Inc. (AMAG) reported adjusted earnings of $1.36 per share in the fourth quarter of 2016, up from $1.04 in the year ago quarter.
Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More
by Zacks Equity Research
The Q4 earnings season is on its last legs as results from 358 S&P 500 members or 71.6% of the index's total membership is already out.